AA
FATE icon

AlphaCentric Advisors’s Fate Therapeutics FATE Stock Holding History

AlphaCentric Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-500
Closed -$20K – 215
2020
Q3 		$20K Hold
500
– – 0.01% 147
2020
Q2 		$17K Buy
+500
New +$14.9K 0.01% 125

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AlphaCentric Advisors's FATE Position: Q4 2020 in Review

AlphaCentric Advisors sold out of Fate Therapeutics (FATE) in Q4 2020, closing a stake of 500 shares — an estimated $20K sold.

AlphaCentric Advisors first reported a position in FATE in Q2 2020 and held it in 2 quarters. The position peaked at $20K in Q3 2020. 248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

  • AlphaCentric Advisors reported no remaining Fate Therapeutics position as of Q4 2020 after selling out during the quarter.
  • AlphaCentric Advisors sold 500 Fate Therapeutics shares in Q4 2020, an estimated $20K.
  • AlphaCentric Advisors first reported a position in Fate Therapeutics in Q2 2020 and held it in 2 quarters.
  • AlphaCentric Advisors's Fate Therapeutics position peaked at $20K in Q3 2020.
  • 248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on AlphaCentric Advisors's 13F filing for Q4 2020, filed 11 Mar 2022.